Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 1998

View Archived Issues

Therapeutic Antibodies updates pipeline

Company Profile: PPL Therapeutics

Elan updates nicotine patch studies and its late-stage development pipeline

VIMRx and Columbia terminate research agreements

Pfizer: analysts' meeting highlights

Potent antifungal triazoles reported by Sankyo

Astra claims novel NOS inhibitors for asthma, rheumatoid arthritis and pain

Central muscarinic receptor agonists patented by U. of Toledo

Phase II clinical trial demonstrates ALX1-11 effective in treating osteoporosis

Novel compounds from P&G behave as alpha2-adrenoceptor agonists

Japanese lab prepares new, broad-spectrum carbapenems

Biomira initiates pivotal phase III trial of Theratope vaccine

StressGen's protein fusion vaccines elicit potent immune response without additional adjuvants

CuraGen, Glaxo Wellcome initiate collaborative pharmacogenomics-based drug discovery effort

Patent covering cytokine trap technology issued to Regeneron

Isis patents antisense oligonucleotides for cancer treatment

FDA approves Sandostatin LAR once-monthly depot formulation

PSC-833 plus chemotherapy is safe and effective in older patients with AML

Safer and more effective SERM compounds reported in development at Signal

Photogen initiates development of ocular disease Rx; receives U.S. patents for technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...